Loading filters...
Publications per Year (2137 total)
5
1990
2
·
6
·
3
·
3
·
3
1995
8
·
1
·
6
·
8
·
9
2000
17
·
15
·
22
·
27
·
31
2005
31
·
53
·
56
·
81
·
86
2010
102
·
92
·
90
·
110
·
130
2015
105
·
120
·
123
·
92
·
93
2020
99
·
91
·
107
·
103
·
138
2025
69
·
Loaded
Click to load
50 / 2137 papers loaded(scroll for more)
202650 papers
ImmunotherapyAll Stages2026
Correcting Mitochondrial Complex I Defect in Tumor-Associated Natural Killer Cells Potentiates Immunotherapy for Glioblastoma.
Zhou N et al. Cancer Discov. 2026
ImmunotherapyAll Stages2026
Consensus statement on microglial and macrophage functions in gliomas.
Zheng Y et al. Acta Neuropathol. 2026
MGMT methylatedAll Stages2026
Invasion/metastasis-related differentially methylated genes predict prognosis in diffuse gliomas.
Zhang S et al. J Neurooncol. 2026
Immunotherapyearly2026
Immune checkpoint inhibitors in pediatric central nervous system tumors: biology, clinical experience, and translational pathways to precision immunotherapy.
Yenidogan I et al. J Neurooncol. 2026
ImmunotherapyAll Stages2026
YBX1&YBX3 as novel targets to potentiate immune checkpoint blockade response in gliomas.
Ali H et al. Neuro Oncol. 2026
Immunotherapyadvanced2026
Phase 1/2 study of a WT1 peptide-dosing emulsion in pediatric patients with recurrent/refractory diffuse intrinsic pontine glioma, glioblastoma, or anaplastic astrocytoma.
Hashii Y et al. Eur J Cancer. 2026
Generalearly2026
Treatment patterns and outcomes in high-risk WHO grade 2 diffuse glioma: a multicentre retrospective cohort study.
Jia JL et al. J Neurooncol. 2026
Generalearly2026
Clinical, molecular, and immunologic determinants of survival in WHO-defined IDH-wildtype glioblastoma treated with radiotherapy: a large real-world cohort study.
Friedes C et al. J Neurooncol. 2026
ImmunotherapyAll Stages2026
A Deep Learning-Driven Framework Integrating Organoid-Based Functional Validation Identifies Universal Neoantigens from Recurrent Glioma Mutations.
Wang C et al. Cancer Res. 2026
MGMT methylatedearly2026
Tumor treating fields for newly diagnosed glioblastoma: a retrospective analysis.
Wang C et al. J Neurooncol. 2026
ImmunotherapyAll Stages2026
Autoimmune Encephalitis as Treatment-Responsive Cause of Rapidly Progressive Dementia: A Multicenter Prospective Cohort Study.
van Steenhoven RW et al. Neurology. 2026
ImmunotherapyAll Stages2026
Enhancing Immune Cell Trafficking to Brain Tumors: Recent Advances and Therapeutic Strategies.
Tong Z et al. Neuro Oncol. 2026
Immunotherapyearly2026
The survival impact of combining radiotherapy and immune checkpoint inhibitors in patients with solid tumors: A systematic review and living meta-analysis of randomized controlled trials.
Tomassen ML et al. Eur J Cancer. 2026
ImmunotherapyAll Stages2026
Distinct tumor immune microenvironmental (TIME) landscapes drive divergent immunotherapy responses in glioblastoma.
Weng L et al. Neuro Oncol. 2026
ImmunotherapyAll Stages2026
TIGIT expression dictates the immunosuppressive reprogramming of myeloid cells in glioblastoma.
Asad M et al. Neuro Oncol. 2026
ImmunotherapyAll Stages2026
Single-cell profiling of peripheral and local immune compartments reveal unique genotype-independent prognostic immune signatures across isocitrate dehydrogenase-stratified glioma.
Sussman JH et al. Neuro Oncol. 2026
GeneralAll Stages2026
STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.
Colman H et al. J Clin Oncol. 2026
ImmunotherapyAll Stages2026
SPP1+ macrophages polarized by lactate confer the progression of hypoxic adaptive tumor cells in brain.
Zhang J et al. Neuro Oncol. 2026
ImmunotherapyAll Stages2026
Glioblastoma immunotherapy in the context of the aging immune system: a systematic review and meta-analysis.
Shireman JM et al. J Neurooncol. 2026
Generaladvanced2026
Spatial Transcriptomics Characterisation of Radionecrotic Changes in Glioblastoma Patients.
Seferbekova Z et al. Neuro Oncol. 2026
Generalearly2026
Efficacy of chemoradiotherapy in pediatric H3K27M-mutant diffuse intrinsic pontine glioma: a study based on single-center and SEER data.
Wang D et al. J Neurooncol. 2026
ImmunotherapyAll Stages2026
Deciphering the tumor microenvironment and role of immunotherapy in Diffuse Midline Glioma: a scoping review.
Ramsoomair CK et al. Neuro Oncol. 2026
GeneralAll Stages2026
PTBP1 knockdown reprograms glioma stem cells into neuronal-like cells and suppresses tumorigenesis via the DUSP5-ERK1/2 signaling pathway.
Li C et al. Neuro Oncol. 2026
ImmunotherapyAll Stages2026
Multi-omic landscape of human gliomas from diagnosis to treatment and recurrence.
Piyadasa H et al. Cancer Cell. 2026
Immunotherapyadvanced2026
Phase I trial of Ipatasertib plus Atezolizumab enhances PI3K/AKT pathway immune responses in solid tumors and refractory glioblastoma.
Tiu C et al. Clin Cancer Res. 2026
ImmunotherapyAll Stages2026
Optimal timing of PD-1 inhibitor immunotherapy administration to stereotactic radiosurgery in malignant gliomas: a propensity score-matched multi-institutional cohort study.
O'Leary S et al. J Neurosurg. 2026
MGMT methylatedAll Stages2026
Glioblastoma survival in rural America: a 10-year experience from a quaternary care center.
Pack E et al. J Neurooncol. 2026
ImmunotherapyAll Stages2026
Therapeutic efficacy of dendritic cell vaccination in a novel syngeneic mouse model of diffuse hemispheric glioma, H3 G34-mutant.
Owens GC et al. J Neurooncol. 2026
Generalearly2026
NT-I7, a long-acting interleukin-7, increases lymphocyte counts and induces CD8+ T cell clonotype expansion in patients with newly diagnosed high-grade gliomas.
Butt OH et al. Clin Cancer Res. 2026
IDH mutantAll Stages2026
Ivosidenib and Vorasidenib decrease intratumoral 2-hydroxyglutarate and total choline levels in patients with lower-grade glioma: an in vivo MR Spectroscopy study.
Simicic D et al. Clin Cancer Res. 2026
GeneralAll Stages2026
MGMT promoter methylation status for glioblastoma: defining the clinically relevant cut-off value for pyrosequencing.
Skarin N et al. J Neurooncol. 2026
MGMT methylatedearly2026
Maximal resection improves survival in MGMT methylated very elderly glioblastoma patients.
Jankovic D et al. J Neurooncol. 2026
GeneralAll Stages2026
Pediatric H3 G34-mutant diffuse hemispheric glioma: clinical, imaging and molecular prognostic factors, MGMT expression, and temozolomide response.
Tlais D et al. Acta Neuropathol. 2026
GeneralAll Stages2026
MGMT downregulation by CRISPR/Cas13 RNA-guided RNA targeting enhances glioma cell sensitivity to TMZ chemotherapy.
Prins TJ et al. J Neurooncol. 2026
ImmunotherapyAll Stages2026
Extracellular vesicles as liquid biopsy tools for personalized therapeutic goals in glioblastoma.
Menaceur Vandenbroucke C et al. Brain. 2026
ImmunotherapyAll Stages2026
When Oncogenic Signaling Meets Sex-Biased Immune Evasion.
Li X et al. Cancer Res. 2026
MGMT methylatedadvanced2026
Association of proton pump inhibitor use with outcome of patients with recurrent glioblastoma.
Le Rhun E et al. Eur J Cancer. 2026
GeneralAll Stages2026
Optimal clinicogenetic criteria for post-operative re-irradiation in recurrent glioblastoma: KROG 21-02.
Park S et al. ESMO Open. 2026
AntiangiogenicAll Stages2026
Framework for Statistical Parametric Mapping of the Interactions between Glioblastoma Location, Treatment, Prognostic Variables, and Survival Using a Phase III Trial.
Sanvito F et al. Clin Cancer Res. 2026
Generalearly2026
Phase 1 evaluation of patients with newly diagnosed glioblastoma treated with radiation, nivolumab, and IDO1 enzyme inhibitor BMS-986205.
Lukas RV et al. Clin Cancer Res. 2026
IDH mutantAll Stages2026
Contemporary practice patterns in IDH-mutant glioma management: a multidisciplinary multi-institutional survey.
Lanman TA et al. J Neurooncol. 2026
MGMT methylatedAll Stages2026
A comprehensive clinical, molecular, radiological, and surgical analysis for predicting prognosis in IDH-mutant astrocytoma patients.
Cho M et al. Neuro Oncol. 2026
GeneralAll Stages2026
Clinical Implications of Aberrant Retinoblastoma Signaling in Patients With Grade 4 IDH-Mutant Astrocytoma: A Retrospective Cohort Study.
Maqbool MA et al. Neurology. 2026
IDH mutantAll Stages2026
Long-term administration of the mutant IDH inhibitor DS-1001b suppresses the growth of IDH1-mutant glioma in vitro and in mouse xenograft models and alters epigenetic profiles.
Fujimoto K et al. Acta Neuropathol. 2026
GeneralAll Stages2026
Rate of biopsy prior to resection among patients with high-grade glioma: a nationwide database analysis.
Howard SD et al. J Neurosurg. 2026
ImmunotherapyAll Stages2026
Vaccine therapy for pediatric high-grade glioma: current landscape, challenges, and future directions.
Harper SD et al. J Neurooncol. 2026
MGMT methylatedAll Stages2026
Early distant progression in adult Histone-3 K27-altered diffuse midline gliomas.
Grassl N et al. J Neurooncol. 2026
ImmunotherapyAll Stages2026
De novo H3.3K27M-altered diffuse midline glioma in human brainstem organoids to dissect GD2 CAR T cell function.
Bessler N et al. Nat Cancer. 2026
GeneralAll Stages2026
Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.
Wen PY et al. J Clin Oncol. 2026
Generalearly2026
Survival and function in elderly patients with GBM: the role of surgical resection with contemporary multimodal therapy.
Song R et al. J Neurooncol. 2026